Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates
27.5.2026 16:00:00 CEST | Business Wire | Press Release
Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features.
The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing.
The Market Shift: Financing as a Growth Lever for B2B Tech Companies
The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting.
Capchase replaces those bottlenecks with financing tech embedded directly into sales tools such as Salesforce, enabling 97% of lending applications to be vetted and decisioned in under 30 seconds.
“For a cybersecurity company like Barracuda, the ability to offer customers flexible subscription financing, with and through our partner ecosystem — without the delays of traditional lenders — directly translates to faster deal cycles and stronger customer relationships. Capchase has become a genuine competitive advantage for our channel.”
— Geoff Waters, CRO, Barracuda Networks
In today’s macroeconomic environment, buyers face budget constraints and tighter cash controls from their CFOs, who prioritize cash preservation over sales enablement. Capchase helps sales leaders access the tech they need without requiring large, upfront payments or waiting for the customer’s next budget approval cycle.
“What we look for in a financing partner is straightforward: they need to move at the speed of the channel. Capchase does exactly that. Quotes turn into approvals in minutes—not days—and that velocity carries through to our sellers and our clients. That’s the standard partners should be held to in 2026.”
— Rob Zack, Vice Chair, MicroAge
The Only Salesforce-Native Financing Platform for Enterprise Tech Vendors
Capchase is the only platform that’s both the lender and the lending infrastructure. Banks have capital but lack speed and software. SaaS and POS partners don’t lend capital directly. Capchase offers both at the speed of tech.
"We moved away from our previous financing provider when it became clear they couldn’t match the speed, technology, or certainty of funding that Capchase offers. What once required hours of forms, email chains, and back-and-forth with customers now happens in minutes directly within Salesforce. Financing used to be a friction point in our sales motion. With Capchase, it became a growth driver."
— Stephanie Southard, Head of Sales, Datarails
AI-Enabled Underwriting & Lending: From Days to Minutes
Capchase AI powers core platform functionality such as underwriting, proposals, purchase order generation, and deal management workflows. But today, Capchase launches a new AI-native product to further streamline the financing process.
Our Agentic Lending Coordinator collects quotes, POs, emails, and other documents, and converts them into an executable loan package instantly. It then manages multi-party collaboration between vendors, partners, and buyers from package review through signing. Since the beta launch, Capchase customers have seen an 8-hour process condensed into a 60-second automation.
Fortune 500 Tech Companies Run on Capchase’s Financing Infrastructure
Capchase’s category leadership is reflected in its growing customer ecosystem, including Barracuda (mission-critical cybersecurity platforms), CDW and Insight (the largest IT solution providers in North America), and MicroAge (which extends financing to the mid-market segment via the reseller channel).
These partnerships highlight where financing demand is strongest: multi-party enterprise tech deals where speed determines outcomes.
“Traditional financing lenders have capital but lack technology, speed, and scale. By becoming both the lender and the infrastructure for vendor financing, we’re making it a growth lever for sales teams, rather than a bottleneck.”
— Miguel Fernandez, CEO & Co-Founder, Capchase
About Capchase
Capchase is a vendor financing platform and lender that helps enterprise technology companies close more deals by offering instant financing to their buyers. We’ve transformed the vendor financing process by embedding underwriting, origination, and deal management directly into sales workflows, and generating loan proposals and documents with the help of AI agents.
Founded in 2020, Capchase serves enterprise tech companies and channel partners, including Barracuda, Verkada, Motive, Okta, Datarails, CDW, Netradyne, and Insight. Capchase is based in New York, with offices in San Francisco and Madrid, and is backed by leading fintech investors QED, Invesco, Thomvest, and 01 Advisors.
Vendor financing at the speed of tech.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260527647157/en/
Contacts
Media contact: Ally Basak, Kindling Collective
415-990-8370
ally@kindling-collective.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press Release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press Release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom